Ultramicronized Palmitoylethanolamide (um-PEA): A New Possible Adjuvant Treatment in COVID-19 patients

Ultramicronized Palmitoylethanolamide (um-PEA): A New Possible Adjuvant Treatment in COVID-19 patients

The Coronavirus Disease-19 (COVID-19) pandemic has caused more than 100,000,000 cases of coronavirus infection in the world in just a year, of which there were 2 million deaths. Its clinical picture is characterized by pulmonary involvement that culminates, in the most severe cases, in acute respira...

Full description

Bibliographic Details
Main Authors: Annalisa Noce, Maria Albanese, Giulia Marrone, Manuela Di Lauro, Anna Pietroboni Zaitseva, Daniela Palazzetti, Cristina Guerriero, Agostino Paolino, Giuseppa Pizzenti, Francesca Di Daniele, Annalisa Romani, Cartesio D’Agostini, Andrea Magrini, Nicola Biagio Mercuri, Nicola Di Daniele
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Pharmaceuticals
Subjects:
COVID-19
SARS-CoV-2
ultramicronized palmitoylethanolamide
organ damage
neuroinflammation
adjuvant treatment
Online Access:https://www.mdpi.com/1424-8247/14/4/336

Internet

https://www.mdpi.com/1424-8247/14/4/336

Similar Items